<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118510</article-id><article-id pub-id-type="publisher-id">ACM-44601</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_17520440.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  急性髓系白血病(AML)院内感染的相关因素分析
  Analysis of Related Factors of Nosocomial Infection in Patients with Acute Myeloid Leukemia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>丽琴</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贾</surname><given-names>振丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>震</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛市黄岛区人民医院血液科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3498</fpage><lpage>3503</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探究急性髓系白血病(Acute myelogenous leukemia, AML)院内感染的相关因素，及时给予早期诊断和早期治疗。方法：回顾性分析自2011年1月至2020年1月收治我院血液科的131例患者，根据是否存在院内感染进行分组，即感染组和非感染组。感染组AML患者64例，包括30例男性，34例女性；非感染组AML患者67例，包括32例男性，35例女性。统计并记录患者的一般基准资料，凝血指标，利用单因素分析和Logistic回归性分析，多因素分析，评估相关因素。结果：结果显示，WBC，APTT，PT，D-D，FIB和血红蛋白是影响AML患者院内感染的相关因素(P &lt; 0.05)。相关因素赋值如下：WBC &lt; 2.0 &#215; 10
  <sup>9</sup>/L为1，WBC ≥ 2.0 &#215; 10
  <sup>9</sup>/L为2；APTT &lt; 33 s为1，APTT ≥ 33 s为2；PT &lt; 10 s为1，PT ≥ 10 s为2；D-D &lt; 0.2 ng/L为1，D-D ≥ 0.2 ng/L为2；FIB &lt; 4 g/L为1，FIB ≥ 4 g/L为2；血红蛋白 &lt; 60 g/L为1，血红蛋白 ≥ 60 g/L为2。多因素分析结果显示，WBC ≥ 2.0 &#215; 10
  <sup>9</sup>/L，APTT ≥ 33 s，PT ≥ 10 s，D-D ≥ 0.2 ng/L，FIB ≥ 4 g/L和血红蛋白 &lt; 60 g/L是影响AML患者院内感染的危险因素。结论：WBC ≥ 2.0 &#215; 109/L，APTT ≥ 33 s，PT ≥ 10 s，D-D ≥ 0.2 ng/L，FIB ≥ 4 g/L和血红蛋白 &lt; 60 g/L是影响AML患者院内感染的危险因素，应及时给予早期诊断和早期治疗。
   Objective: To explore the related factors of nosocomial infection in acute myelogenous leukemia (AML), and to give early diagnosis and treatment. Methods: From January 2011 to January 2020, 131 patients in the Department of Hematology of our hospital were retrospectively analyzed. They were divided into infection group and non infection group according to whether there was nosocomial infection. In the infection group, there were 64 AML patients, including 30 males and 34 females. There were 67 AML patients in non infection group, including 32 males and 35 females. The general baseline data and coagulation indexes of the patients were recorded. Univariate analysis, logistic regression analysis and multivariate analysis were used to evaluate the related factors. Results: The results showed that WBC, APTT, PT, D-D, FIB and hemoglobin were the related factors of nosocomial infection in AML patients (P &lt; 0.05). The related factors were assigned as follows: WBC &lt; 2.0 &#215; 10
  <sup>9</sup> / L is 1, WBC ≥ 2.0 &#215; 109/L is 2; APTT &lt; 33 s is 1, APTT ≥ 33 s is 2; PT &lt; 10 s is 1, PT ≥ 10 s is 2; D-D &lt; 2 ng/L is 1, D-D ≥ 0.2 ng/L is 2; FIB &lt; 4 g/L is 1, FIB ≥ 4 g/L is 2; hemoglobin &lt; 60 g/L is 1, hemoglobin ≥ 60 g/L is 2. The results of multivariate analysis showed that WBC ≥ 2.0 &#215; 10
  <sup>9</sup>/L, APTT ≥ 33 s, PT ≥ 10 s, D-D ≥ 0.2 ng/L, FIB ≥ 4 g/L and hemoglobin &lt; 60 g/L were risk factors for nosocomial infection in AML patients. Conclusion: WBC ≥ 2.0 &#215; 10
  <sup>9</sup>/L, APTT ≥ 33 s, PT ≥ 10 s, D-D ≥ 0.2 ng/L, FIB ≥ 4 g/L and hemoglobin &lt; 60 g/L are the risk factors of nosocomial infection in AML patients. Early diagnosis and treatment should be given in time.
 
</p></abstract><kwd-group><kwd>急性髓系白血病，感染，凝血指标，早期预防, Acute Myeloid Leukemia</kwd><kwd> Infected</kwd><kwd> Coagulation Index</kwd><kwd> Early Prevention</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探究急性髓系白血病(Acute myelogenous leukemia, AML)院内感染的相关因素，及时给予早期诊断和早期治疗。方法：回顾性分析自2011年1月至2020年1月收治我院血液科的131例患者，根据是否存在院内感染进行分组，即感染组和非感染组。感染组AML患者64例，包括30例男性，34例女性；非感染组AML患者67例，包括32例男性，35例女性。统计并记录患者的一般基准资料，凝血指标，利用单因素分析和Logistic回归性分析，多因素分析，评估相关因素。结果：结果显示，WBC，APTT，PT，D-D，FIB和血红蛋白是影响AML患者院内感染的相关因素(P &lt; 0.05)。相关因素赋值如下：WBC &lt; 2.0 &#215; 10<sup>9</sup>/L为1，WBC ≥ 2.0 &#215; 10<sup>9</sup>/L为2；APTT &lt; 33 s为1，APTT ≥ 33 s为2；PT &lt; 10 s为1，PT ≥ 10 s为2；D-D &lt; 0.2 ng/L为1，D-D ≥ 0.2 ng/L为2；FIB &lt; 4 g/L为1，FIB ≥ 4 g/L为2；血红蛋白 &lt; 60 g/L为1，血红蛋白 ≥ 60 g/L为2。多因素分析结果显示，WBC ≥ 2.0 &#215; 10<sup>9</sup>/L，APTT ≥ 33 s，PT ≥ 10 s，D-D ≥ 0.2 ng/L，FIB ≥ 4 g/L和血红蛋白 &lt; 60 g/L是影响AML患者院内感染的危险因素。结论：WBC ≥ 2.0 &#215; 10<sup>9</sup>/L，APTT ≥ 33 s，PT ≥ 10 s，D-D ≥ 0.2 ng/L，FIB ≥ 4 g/L和血红蛋白 &lt; 60 g/L是影响AML患者院内感染的危险因素，应及时给予早期诊断和早期治疗。</p></sec><sec id="s2"><title>关键词</title><p>急性髓系白血病，感染，凝血指标，早期预防</p></sec><sec id="s3"><title>Analysis of Related Factors of Nosocomial Infection in Patients with Acute Myeloid Leukemia<sup> </sup></title><p>Liqin Xu, Zhenli Jia, Zhen Wang</p><p>Department of Blood of Huangdao People’s Hospital of Qingdao, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/27-1572447x4_hanspub.png?20210818181139836" /></p><p>Received: Jul. 11<sup>th</sup>, 2021; accepted: Aug. 11<sup>th</sup>, 2021; published: Aug. 18<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/27-1572447x5_hanspub.png?20210818181139836" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the related factors of nosocomial infection in acute myelogenous leukemia (AML), and to give early diagnosis and treatment. Methods: From January 2011 to January 2020, 131 patients in the Department of Hematology of our hospital were retrospectively analyzed. They were divided into infection group and non infection group according to whether there was nosocomial infection. In the infection group, there were 64 AML patients, including 30 males and 34 females. There were 67 AML patients in non infection group, including 32 males and 35 females. The general baseline data and coagulation indexes of the patients were recorded. Univariate analysis, logistic regression analysis and multivariate analysis were used to evaluate the related factors. Results: The results showed that WBC, APTT, PT, D-D, FIB and hemoglobin were the related factors of nosocomial infection in AML patients (P &lt; 0.05). The related factors were assigned as follows: WBC &lt; 2.0 &#215; 10<sup>9</sup> / L is 1, WBC ≥ 2.0 &#215; 10<sup>9</sup>/L is 2; APTT &lt; 33 s is 1, APTT ≥ 33 s is 2; PT &lt; 10 s is 1, PT ≥ 10 s is 2; D-D &lt; 2 ng/L is 1, D-D ≥ 0.2 ng/L is 2; FIB &lt; 4 g/L is 1, FIB ≥ 4 g/L is 2; hemoglobin &lt; 60 g/L is 1, hemoglobin ≥ 60 g/L is 2. The results of multivariate analysis showed that WBC ≥ 2.0 &#215; 10<sup>9</sup>/L, APTT ≥ 33 s, PT ≥ 10 s, D-D ≥ 0.2 ng/L, FIB ≥ 4 g/L and hemoglobin &lt; 60 g/L were risk factors for nosocomial infection in AML patients. Conclusion: WBC ≥ 2.0 &#215; 10<sup>9</sup>/L, APTT ≥ 33 s, PT ≥ 10 s, D-D ≥ 0.2 ng/L, FIB ≥ 4 g/L and hemoglobin &lt; 60 g/L are the risk factors of nosocomial infection in AML patients. Early diagnosis and treatment should be given in time.</p><p>Keywords:Acute Myeloid Leukemia, Infected, Coagulation Index, Early Prevention</p><disp-formula id="hanspub.44601-formula11"><graphic xlink:href="//html.hanspub.org/file/27-1572447x6_hanspub.png?20210818181139836"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/27-1572447x7_hanspub.png?20210818181139836" /> <img src="//html.hanspub.org/file/27-1572447x8_hanspub.png?20210818181139836" /></p></sec><sec id="s5"><title>1. 引言</title><p>急性髓系白血病(Acute myelogenous leukemia, AML)是临床上血液科常见的疾病之一，属于白血病的类型之一，多见于老年人，而且随着我国人口老龄化社会的不断加剧，AML的发病率也在逐年增高 [<xref ref-type="bibr" rid="hanspub.44601-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44601-ref2">2</xref>]。针对AML的研究，目前除了积极寻找新的治疗方法，提高治愈率，预防病死率也是另外一种思路，相对于新治疗方法的难度而言，预防其院内感染的发病率，降低死亡率，也是临床上应该重视的问题 [<xref ref-type="bibr" rid="hanspub.44601-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.44601-ref4">4</xref>]。因为在AML的治疗中，患者因为院内感染而死去的比例也在逐年上升，因此，针对其易感因素进行干预也是AML患者治疗和护理过程中较为重要的措施 [<xref ref-type="bibr" rid="hanspub.44601-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.44601-ref6">6</xref>]。因此，本研究根据我们的临床工作实践，回顾性分析自2011年1月至2020年1月收治我院血液科的131例患者，根据是否存在院内感染进行分组，统计并记录患者的一般基准资料，凝血指标，利用单因素分析和Logistic回归性分析多因素，以期为临床上AML发生院内感染患者的预防提供依据。</p></sec><sec id="s6"><title>2. 资料和方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>本研究为回顾性病例对照研究，以2011年1月至2020年1月收治我院血液科的131例AML患者为研究对象，所有患者均签署知情同意书，获得伦理本院伦理委员会许可。</p></sec><sec id="s6_2"><title>2.2. 纳入标准</title><p>① 术前入组患者门诊入院，具备白血病的症状和体征；</p><p>② 所有入组患者均经过骨穿，活检证实AML的诊断；</p><p>③ 入组者无明显的心肺功能疾病，比如肺功能不全，心功能不全，肾功能不全等疾病；</p><p>④ 入组者患者无其他血液类疾病，比如再生障碍性贫血，凝血功能障碍等疾病，排除其他相关疾病；</p><p>⑤ 入组者无严重的心理疾病，包括人格分裂等心理疾病；</p><p>⑥ 入组者均对研究的内容和目的，同意研究方案，并签署知情同意书。</p></sec><sec id="s6_3"><title>2.3. 排除标准</title><p>① 心肺功能不全的AML患者；</p><p>② 不具备生活自理能力的AML患者；</p><p>③ 不同意该研究方案，拒绝服从医护指导的患者；</p><p>④ 未签署知情同意书的患者。</p></sec><sec id="s6_4"><title>2.4. 试验分组</title><p>根据是否存在院内感染情况，将入组131例AML患者分成两组，即感染组和非感染组。感染组AML患者包括64例，包括30例男性，34例女性；非感染组AML患者包括67例，包括32例男性，35例女性。</p></sec><sec id="s6_5"><title>2.5. 抗感染处理方案</title><p>取院内感染患者的口咽分泌物，进行分泌物药物敏感性检测，根据药敏试验结果进行抗感染处理。</p></sec><sec id="s6_6"><title>2.6. 监测指标</title><p>1) 患者的一般资料：包括年龄，性别，BMI指数等；</p><p>2) 患者的血清学指标：包括PT (血浆凝血酶时间)，TT (凝血酶时间)，APTT (活化部分凝血活酶时间)，FIB (血浆纤维蛋白原)，WBC (白细胞计数)，NEUT (中性粒细胞计数)，血红蛋白，血小板计数和D-二聚体(D-D)。</p></sec><sec id="s6_7"><title>2.7. 统计学分析</title><p>统计学处理用SPSS 22.0软件来进行。统计资料结果用均数 &#177; 标准差(x &#177; s)来表示，秩和检验来比较评分均数，t检验比较其它独立样本均数。多因素分析采用Logistc法，P &lt; 0.05表示差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 影响AML患者院内感染的单因素分析结果</title><p>结果显示，WBC，APTT，PT，D-D，FIB和血红蛋白是影响AML患者院内感染的相关因素(P &lt; 0.05)。见表1。</p><p>相关因素赋值如下：WBC &lt; 2.0 &#215; 10<sup>9</sup>/L为1，WBC ≥ 2.0 &#215; 10<sup>9</sup>/L为2；APTT &lt; 33 s为1，APTT ≥ 33 s为2；PT &lt; 10 s为1，PT ≥ 10 s为2；D-D &lt; 0.2 ng/L为1，D-D ≥ 0.2 ng/L为2；FIB &lt; 4 g/L为1，FIB ≥ 4 g/L为2；血红蛋白 &lt; 60 g/L为1，血红蛋白 ≥ 60 g/L为2。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The univariate analysis results of nosocomial infection in patients with AM</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >因素</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >感染组 (n = 64)</th><th align="center" valign="middle" >非感染组 (n = 67)</th><th align="center" valign="middle" >c<sup>2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.215</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >&lt;65岁</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥65岁</td><td align="center" valign="middle" >86</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.327</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >BMI (Kg/m<sup>2</sup>)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.287</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >&lt;28</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥28</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >WBC</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8.329</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >&lt;2.0 &#215; 10<sup>9</sup>/L</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥2.0 &#215; 10<sup>9</sup>/L</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血小板计数</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.316</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >&lt;100 &#215; 10<sup>9</sup>/L</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥100 &#215; 10<sup>9</sup>/L</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >APTT</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >9.327</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >&lt;33 s</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥33 s</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >PT</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8.097</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >&lt;10 s</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥10 s</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >D-D</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >9.701</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >&lt;0.2 ng/L</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥0.2 ng/L</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >FIB</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8.114</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >&lt;4 g/L</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥4 g/L</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血红蛋白</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >9.977</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >&lt;60 g/L</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥60 g/L</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 影响AML患者院内感染的单因素分析结果</p></sec><sec id="s7_2"><title>3.2. 影响AML患者院内感染的多因素分析结果</title><p>结果显示，WBC ≥ 2.0 &#215; 10<sup>9</sup>/L，APTT ≥ 33 s，PT ≥ 10 s，D-D ≥ 0.2 ng/L，FIB ≥ 4 g/L和血红蛋白 &lt; 60 g/L是影响AML患者院内感染的危险因素。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The results of multivariate analysis of nosocomial infection in patients with AM</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >自变量</th><th align="center" valign="middle" >回归系数</th><th align="center" valign="middle" >标准误差</th><th align="center" valign="middle" >标准回归系数</th><th align="center" valign="middle" >t值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >常数项</td><td align="center" valign="middle" >47.051</td><td align="center" valign="middle" >2.865</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >15.195</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >WBC</td><td align="center" valign="middle" >3.791</td><td align="center" valign="middle" >0.524</td><td align="center" valign="middle" >0.506</td><td align="center" valign="middle" >4.015</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >APTT</td><td align="center" valign="middle" >3.791</td><td align="center" valign="middle" >0.524</td><td align="center" valign="middle" >0.506</td><td align="center" valign="middle" >4.015</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >PT</td><td align="center" valign="middle" >3.658</td><td align="center" valign="middle" >0.494</td><td align="center" valign="middle" >0.498</td><td align="center" valign="middle" >3.674</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >D-D</td><td align="center" valign="middle" >3.981</td><td align="center" valign="middle" >0.804</td><td align="center" valign="middle" >0.726</td><td align="center" valign="middle" >4.009</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >FIB</td><td align="center" valign="middle" >3.986</td><td align="center" valign="middle" >0.866</td><td align="center" valign="middle" >0.741</td><td align="center" valign="middle" >5.769</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >血红蛋白</td><td align="center" valign="middle" >3.421</td><td align="center" valign="middle" >0.697</td><td align="center" valign="middle" >0.573</td><td align="center" valign="middle" >4.016</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表2. 影响AML患者院内感染的多因素分析结果</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>随着我国经济社会的不断发展，以及老龄化社会的加剧，血液疾病的发病率也在逐年上升，极大的威胁了人们的健康问题。其中，据流行病学统计，我国每年新增的血液疾病病例可达几十万，并且，急性髓系白血病(Acute myelogenous leukemia, AML)的发病率占所有血液学疾病的70%以上，多见于老年人 [<xref ref-type="bibr" rid="hanspub.44601-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44601-ref8">8</xref>]。AML的病理特点以幼稚髓系细胞异常增殖为主，可以广泛侵及淋巴结，肝脾，关节，骨组织和皮肤等，对正常人的全身情况造成较大的负担，从而降低患者的免疫能力，容易导致感染的发生，而AML患者感染后，其生存时间和生活质量也大打折扣 [<xref ref-type="bibr" rid="hanspub.44601-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.44601-ref10">10</xref>]。因此，如何预防AML患者发生感染是目前临床上的研究热点问题。</p><p>既往研究表明，急性髓系白血病(Acute myelogenous leukemia, AML)患者的感染率明显高于普通患者，约是普通患者的10倍左右，分析其原因，可能是AML患者可以降低患者的免疫力，从而导致各种感染相关疾病的发生，比如肺部感染，褥疮和全身脓毒症的发生等 [<xref ref-type="bibr" rid="hanspub.44601-ref11">11</xref>]。也有研究证明，凝血功能与感染的发生密切相关，其中，APTT是一种内源性凝血指标，当内源性凝血酶原和凝血因子减少时，APTT水平大量升高。此外，FIB作为血液凝固指标，在患者存在感染后，FIB含量就会增加，进而引起纤溶活性减弱 [<xref ref-type="bibr" rid="hanspub.44601-ref12">12</xref>]。与之前研究结果相似，在本研究中，我们发现WBC，APTT，PT，D-D，FIB和血红蛋白是影响AML患者院内感染的相关因素(P &lt; 0.05)。并且为了进一步进行多因素分析，相关因素赋值如下：WBC &lt; 2.0 &#215; 10<sup>9</sup>/L为1，WBC ≥ 2.0 &#215; 10<sup>9</sup>/L为2；APTT &lt; 33 s为1，APTT ≥ 33 s为2；PT &lt; 10 s为1，PT ≥ 10 s为2；D-D &lt; 0.2 ng/L为1，D-D ≥ 0.2 ng/L为2；FIB &lt; 4 g/L为1，FIB ≥ 4 g/L为2；血红蛋白 &lt; 60 g/L为1，血红蛋白 ≥ 60 g/L为2。结果显示，WBC ≥ 2.0 &#215; 10<sup>9</sup>/L，APTT ≥ 33 s，PT ≥ 10 s，D-D ≥ 0.2 ng/L，FIB ≥ 4 g/L和血红蛋白 &lt; 60 g/L为影响AML患者院内感染的危险因素。分析其原因，可能是凝血功能的改变，会增加患者的感染率，因此，对于此类患者应该密切监测其感染指标，并且及时给予抗感染治疗。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，WBC ≥ 2.0 &#215; 10<sup>9</sup>/L，APTT ≥ 33 s，PT ≥ 10 s，D-D ≥ 0.2 ng/L，FIB ≥ 4 g/L和血红蛋白 &lt; 60 g/L是影响AML患者院内感染的危险因素，应及时给予早期诊断和早期治疗。</p></sec><sec id="s10"><title>文章引用</title><p>许丽琴,贾振丽,王 震. 急性髓系白血病(AML)院内感染的相关因素分析Analysis of Related Factors of Nosocomial Infection in Patients with Acute Myeloid Leukemia[J]. 临床医学进展, 2021, 11(08): 3498-3503. https://doi.org/10.12677/ACM.2021.118510</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44601-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">DiNardo, C.D., Maiti, A., Rausch, C.R., et al. (2020) 10-Day Decitabine with Venetoclax for Newly Diagnosed Intensive Chemotherapy Ineligible, and Relapsed or Refractory Acute Myeloid Leukaemia: A Single-Centre, Phase 2 Trial. The Lancet Haematology, 7, 724-736. &lt;br&gt;https://doi.org/10.1016/S2352-3026(20)30210-6</mixed-citation></ref><ref id="hanspub.44601-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Platzbecker, U., Middeke, J.M., Sockel, K., et al. (2018) Measurable Residual Disease-Guided Treatment with Azacitidine to Prevent Haematological Relapse in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukaemia (RELAZA2): An Open-Label, Multicentre, Phase 2 Trial. The Lancet Oncology, 19, 1668-1679.  
&lt;br&gt;https://doi.org/10.1016/S1470-2045(18)30580-1</mixed-citation></ref><ref id="hanspub.44601-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Anguille, S., Van de Velde, A.L., Smits, E.L., et al. (2017) Dendritic Cell Vaccination as Postremission Treatment to Prevent or Delay Relapse in Acute Myeloid Leukemia. Blood, 130, 1713-1721.  
&lt;br&gt;https://doi.org/10.1182/blood-2017-04-780155</mixed-citation></ref><ref id="hanspub.44601-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">姜巧丽, 樊浩然, 赵东亮. 急性髓系白血病化疗患者凝血功能与其感染关系及相关因素分析[J]. 四川解剖学杂志, 2020, 28(3): 161-162.</mixed-citation></ref><ref id="hanspub.44601-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">陈晓敏, 唐柳, 刘洋, 等. 成人急性淋巴细胞白血病患者化疗期间院内感染的病原菌分布和耐药情况, 危险因素分析[J]. 山东医药, 2020, 1164(6): 63-66.</mixed-citation></ref><ref id="hanspub.44601-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">崔清彦, 张婷, 陈森. 儿童急性淋巴细胞白血病化疗后感染的临床特征及危险因素分析[J]. 中国现代医学杂志, 2020, 30(23): 78-82.</mixed-citation></ref><ref id="hanspub.44601-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sung, L., Aplenc, R., Alonzo, T.A., et al. (2016) Association between Prolonged Neutropenia and Reduced Relapse Risk in Pediatric AML: A Report from the Children’s Oncology Group. International Journal of Cancer, 139, 1930-1935.  
&lt;br&gt;https://doi.org/10.1002/ijc.30236</mixed-citation></ref><ref id="hanspub.44601-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ballo, O., Kreisel, E.M., Eladly, F., et al. (2020) Use of Carbapenems and Glycopeptides Increases Risk for Clostridioides Difficile Infections in Acute Myeloid Leukemia Patients Undergoing Intensive Induction Chemotherapy. Annals of Hematology, 99, 2547-2553. &lt;br&gt;https://doi.org/10.1007/s00277-020-04274-1</mixed-citation></ref><ref id="hanspub.44601-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Demichelis-Gómez, R., Zapata-Canto, N., Leyto-Cruz, F., et al. (2020) Acute Myeloid Leukemia in Mexico: The Specific Challenges of a Developing Country. Results from a Multicenter National Registry. Clinical Lymphoma, Myeloma &amp; Leukemia, 20, 295-303. &lt;br&gt;https://doi.org/10.1016/j.clml.2019.12.015</mixed-citation></ref><ref id="hanspub.44601-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rodríguez-Veiga, R., Montesinos, P., Boluda, B., et al. (2019) Incidence and Outcome of Invasive Fungal Disease after Front-Line Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Impact of Antifungal Prophylaxis. Annals of Hematology, 98, 2081-2088. &lt;br&gt;https://doi.org/10.1007/s00277-019-03744-5</mixed-citation></ref><ref id="hanspub.44601-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">肖喜春, 司金春, 陈淑霞, 等. 老年急性髓系白血病患者化疗期间医院感染的危险因素及防治[J]. 中华实验和临床感染病杂志(电子版), 2014(5): 631-634.</mixed-citation></ref><ref id="hanspub.44601-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">朱齐兵, 陈慧君, 唐小万, 等. 急性白血病患者化疗后血流感染病原菌分布及危险因素分析[J]. 中国医药, 2018(1): 104-107.</mixed-citation></ref></ref-list></back></article>